ACP Journal Club. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors.
作者信息
Farkouh Michael
机构信息
Mount Sinai Medical Center, New York, NY, USA.
出版信息
Ann Intern Med. 2010 Jun 15;152(12):JC6-10. doi: 10.7326/0003-4819-152-12-201006150-02010.
Abstract
摘要
相似文献
1
ACP Journal Club. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors.《美国内科医师学会杂志俱乐部》。那格列奈未能降低糖耐量受损且有心血管危险因素患者的糖尿病发生率或心血管事件发生率。
Ann Intern Med. 2010 Jun 15;152(12):JC6-10. doi: 10.7326/0003-4819-152-12-201006150-02010.
2
ACP Journal Club. Valsartan reduced diabetes but not CV events in patients with impaired glucose tolerance and CV risk factors.《美国内科医师学会杂志俱乐部》。缬沙坦可降低糖耐量受损和有心血管危险因素患者的糖尿病发生率，但不能降低心血管事件发生率。
Ann Intern Med. 2010 Jun 15;152(12):JC6-9. doi: 10.7326/0003-4819-152-12-201006150-02009.
3
ACP journal club. Intensive glucose control increased mortality and did not prevent CV events compared with standard glucose control in type 2 diabetes.《美国内科医师学会杂志俱乐部》。与2型糖尿病的标准血糖控制相比，强化血糖控制增加了死亡率且未能预防心血管事件。
Ann Intern Med. 2011 May 17;154(10):JC5-02. doi: 10.7326/0003-4819-154-10-201105170-02002.
4
ACP Journal Club. Adding prompt revascularization to medical therapy did not reduce mortality or CV events in patients with type 2 diabetes and CAD.《美国内科医师学会杂志俱乐部》。对于2型糖尿病合并冠心病患者，在药物治疗基础上增加早期血运重建并不能降低死亡率或心血管事件发生率。
Ann Intern Med. 2009 Oct 20;151(8):JC4-5. doi: 10.7326/0003-4819-151-8-200910200-02005.
5
ACP Journal Club. Daily n-3 fatty acid supplements did not reduce CV events in high-risk patients with dysglycemia.《美国内科医师学会杂志俱乐部》。每日补充n-3脂肪酸并不能降低血糖异常高危患者的心血管事件发生率。
Ann Intern Med. 2012 Sep 18;157(6):JC3-11. doi: 10.7326/0003-4819-157-6-201209180-02011.
6
ACP Journal Club. Review: Intensive glucose control reduced some CV events but did not change mortality in type 2 diabetes.《美国内科医师学会杂志俱乐部》。综述：强化血糖控制可减少部分心血管事件，但未改变2型糖尿病患者的死亡率。
Ann Intern Med. 2009 Sep 15;151(6):JC3-6. doi: 10.7326/0003-4819-151-6-200909150-02006.
7
ACP Journal Club. Intensive and standard glucose control did not differ for major CV events or death in poorly controlled type 2 diabetes.《美国内科医师学会杂志俱乐部》。在控制不佳的2型糖尿病患者中，强化血糖控制与标准血糖控制在主要心血管事件或死亡方面并无差异。
Ann Intern Med. 2009 Mar 17;150(6):JC3-8. doi: 10.7326/0003-4819-150-6-200903170-02008.
8
ACP Journal Club. Daily multivitamin supplements did not reduce risk for major CV events over > 10 years in men.《美国内科医师学会杂志俱乐部》。在超过10年的时间里，男性每日服用多种维生素补充剂并未降低发生重大心血管事件的风险。
Ann Intern Med. 2013 Feb 19;158(4):JC8. doi: 10.7326/0003-4819-158-4-201302190-02008.
9
Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.那格列奈——在2型糖尿病患者治疗中的当前及未来作用
Int J Clin Pract. 2005 Oct;59(10):1218-28. doi: 10.1111/j.1368-5031.2005.00669.x.
10
ACP Journal Club. Review: Statins reduce mortality and cardiovascular (CV) morbidity in patients with low CV risk.《美国内科医师学会杂志俱乐部》。综述：他汀类药物可降低心血管疾病风险较低患者的死亡率和心血管发病率。
Ann Intern Med. 2012 Apr 17;156(8):JC4-07. doi: 10.7326/0003-4819-156-8-201204170-02007.
Zotero 插件